The U.K. Competition and Markets Authority has cleared Roche’s pending acquisition of Spark Therapeutics, ruling the deal would not negatively affect competition, according to a press release.
An investigation by the CMA found that while Spark is developing a gene therapy treatment candidate for hemophilia A that is expected to compete with Roche’s Hemlibra (emicizumab-kxwh), there are other treatments in development from multiple suppliers.
Roche announced in February that it planned to fully acquire Spark for a price of $114.50 per share.
The deal, with a total equity value of more
Uncategorized